Gliclazide potentiates suppression of hepatic glucose production in non- insulin-dependent diabetic patients

Metabolism: Clinical and Experimental

Volumn 45, Issue 10, 1996, Pages 1196-1202

  Riccio, A ^a   Lisato, G ^a   Vigili De Kreutzenberg, S ^a   Marchetto, S ^a   Turrin, M ^a   Tiengo, A ^a   Del Prato, S ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Dipartimento di Medicina Clinica e Sperimentale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029795481     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90235-8     Document Type: Article

References (28)

1. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15: 737-754, 1992
2. Lebovitz HE: Oral hypoglycemic agents, in Rifkin H, Porte D Jr (eds): Diabetes Mellitus: Theory and Practice (ed 4). New York, NY, Excerpta Medica, 1990, pp 554-575
3. Del Prato S, Vigili de Kreutzenberg S, Riccio A, et al: Hepatic sensitivity to insulin. Effects of sulfonylurea drugs. Am J Med 90:29S-36S, 1991 (suppl 6A)
4. De Fronzo RA: Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33:838-845, 1984
5. Kolterman OG: The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics. Diabetes Metab Rev 3:399-414, 1987
6. Best JD, Judzewitsch RG, Pfeifer MA, et al: The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes 33:839-845, 1984
7. Lisato G, Cusin I, Tiengo A, et al: The contribution of hyperglycemia and hypoinsulinemia to the insulin resistance of streptozotocin diabetic rats. Diabetologia 35:310-315, 1992
8. De Fronzo RA, Tobin J, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
9. Ferrannini E, Del Prato S, De Fronzo RA: Glucose kinetics, in Clarke WL, Larner J, Pohl SL (eds): Methods in Diabetes Research, vol 2. New York, NY, Wiley, 1986, pp 707-741
10. Finegood DT, Bergman RN, Vranic M: Estimation of endogenous glucose production during hyperinsulinemic glucose clamps: Comparison of unlabelled and labelled exogenous glucose infusates. Diabetes 36:914-924, 1987
11. Shimizu S, Inoue E, Tani Y, et al: Enzymatic microdetermination of serum free fatty acids. Anal Biochem 98:341-345, 1979
12. Campbell DB, Lavielle R, Nathan C: The mode of action and clinical pharmacology of gliclazide: A review. Diabetes Res Clin Pract 14:S21-S36, 1991 (suppl)
13. Malaisse WJ, Couturver E, Valverde I: The insulinotropic action of gliclazide: Possible mode of action. Int Diabetes Fed Bull 1:20-23, 1987
14. Matthews D, Hosker J, Turner R: Effects of gliclazide on insulin secretion induced by glucose and amino acids. IDF Bull 1:12-15, 1987
15. Kolterman OG, Olefsky JM: The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care 7:81-88, 1984 (suppl 1)
16. Simonson DC, Del Prato S, Castellino P, et al: Effect of glyburide on glycaemic control, insulin requirement and glucose metabolism in insulin-treated diabetic patients. Diabetes 36: 136-146, 1987
17. Batch J, Ma A, Bird D, et al: The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels. Eur J Clin Pharmacol 38:465-467, 1990
18. Groop LC, Bonadonna RC, Del Prato S, et al: Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus: Evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989
19. Polonsky KS, Jaspan JB, Pugh W, et al: Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. J Clin Invest 72:1114-1123, 1983
20. Del Prato S, Riccio A, Vigili de Kreutzenberg S, et al: Basal plasma insulin levels exert a qualitative but not quantitative effect on glucose-mediated glucose uptake. Am J Physiol 268:E1089-E1095, 1995
21. Liljenquist JE, Mueller GL, Cherrington AD, et al: Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59:369-374, 1977
22. Fallucca F, Iavicoli M, Menzinger G, et al: Glucagon and growth hormone secretion in insulin-treated diabetics. Effects of added sulfonylureas. Metabolism 27:5-11, 1978
23. Shepherd RE, Fain JM: Inhibition of rat fat cell triglyceride lipase by sulfonylureas. Fed Proc 36:2732-2734, 1977
24. Ward G, Harrison LC, Proietto J, et al: Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects. Diabetes 34:241-245, 1985
25. Bak J, Schmitz O, Sorensen N, et al: Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes 38:1232-1250, 1989
26. Price BA, Joffe BM, Zinner MY: Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. Gastroenterology 88:80-85, 1985
27. Vestergaard H, Weinreb JE, Rosen AS, et al: Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: A longitudinal study. J Clin Endocrinol Metab 80:270-275, 1995
28. Saccà L, Sherwin R, Hendler R, et al: Influence of continuous hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans. J Clin Invest 63:849-857, 1979